medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2008, Number 3

<< Back Next >>

Arch Neurocien 2008; 13 (3)

Transcraneal sonography in the diagnosis of Parkinson disease

Martínez-Hernández HR, Ríos CLC

Language: Spanish
References: 40
Page: 202-207
PDF size: 102.51 Kb.


ABSTRACT

The advances in Parkinson´s Disease diagnosis are improving the recognition of cases. The transcraneal sonography is a helpful diagnostic tool with a low cost and very good accessibility than shows a substantia nigra hypetechogenicity in the midbrain that is present in more than 90% of case. This finding has been associated with an increase of iron concentration and with a dysfunction in proteins related with its metabolism. In this paper we present a review of this technique since the very first report in 1995 and all the factors that were been implicate in the hyperechogenicity.


REFERENCES

  1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson‘s disease. Lancet Neurol 2006; 5:75-86.

  2. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of sustancia negra in chronic Parkinson´s disease visualized by transcranial color-coded real-time sonography. Neurology 1995; 45(1): 182-4.

  3. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Benz P, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53(5):1026-31.

  4. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, et la. Echogenecity of the sustancia negra association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.

  5. Berg D, Siefker C, Becker G. Echogenicity of the sustancia negra in Parkinson´s disease and its relation to clinical findings. J Neurol 2001; 248: 684-9.

  6. Tanner CM, Aston DA. Epidemiology of Parkinson´s disease and akinetic syndromes. Curr Opin Neurol 2000; 13: 427-30.

  7. Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, et la. Brain iron pathways and their relevance to Parkinson´s disease. J Neuroch 2001; 79: 225-36.

  8. Behnke S, Berg D, Becker G. Does ultrasound disclose a vulnerability factor for Parkinson´s disease?. J Neurol 2003 (Suppl 1):1/24-1/27.

  9. Walter U, Wittstock M, Benecke R, Dressler D. Sustancia negra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson´s disease. J Neural Transm 2002; 109: 191-6.

  10. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predictive value of Transcranial Sonography in the diagnosis of Parkinson´s disease. Mov Disord 2006; 21(10): 1763-65.

  11. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson´s disease and atypical parkinsonian syndromes. Neurology 2003;60:74-7.

  12. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G. Transcranial brain parenchyma sonography in move-ment disorders: state of the art. Ultrasound in Med & Biol 2007; 33(1):15-25.

  13. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the sustancia negra in Parkinson´s disease. Mov Disord 2005, 20;3:383-5.

  14. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Sustancia negra hyperechogenicity as a marker of predisposition and slower progression in Parkinson´s disease. Mov Disord 2006, 21;1: 94-8.

  15. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of Idiopathic Parkinson´s disease. Mov Disord 2007;22(1):48-54.

  16. Ressner P, Skoloudik D, Hlus P, Kanovsky P. Hyperechogenicity of the Sustancia negra in Parkinson’s disease. J Neuroimaging 2007;17:164-7.

  17. Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Relationship of the sustancia negra echogenicity and motor function in elderly subjects. Neurology 2001; 56:13-7.

  18. Behnke S, Double KL, Duma S, Broe GA, Guenther V, Becker G. Sustancia negra echomorphology in the healthy very old: Correlation with motor slowing. NeuroImage 2007; 34: 1054-9.

  19. Iova A, Garmashov A, Androuchtchenko N, Kehrer M, Berg D, Becker G. Postnatal decrease in sustancia negra echogenicity. Implications for the pathogenesis of Parkinson’s disease. J Neurol 2004; 251: 1451-4.

  20. Ruprecht-Dôrfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL. Echogenicity of the sustancia negra in relatives of patients with sporadic Parkinson‘s disease. Neuroimage 2003; 18:416-22.

  21. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of Sustancia negra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 2001;50: 463-7.

  22. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of sbstantia nigra damage. Mov Disord 2005 20; 10: 1278-85.

  23. Berg D. In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of sustancia negra. J Neural Transm 2006; 113: 775-80.

  24. Berg D. Disturbance of Iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson´s disease: Implications for Idiopathic and Monogenenetic forms. Neurochem Res 2007; Apr 28; [Epub adelantado al impreso].

  25. 25.Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson´s disease and atypical parkinsonian syndromes. Neurology 2003;60:74-7.

  26. Behnke S, Berg D, Nuamann M, Becker G. Differentiation of Parkinson‘s disease and atypical parkinsonian syndromes by transcranial ultrasound. J Nuerol Neurosurg Psychiatry 2005; 76:423-5.

  27. Walter U, Dressler D, Probst T, Wolters A, Abu-Mugheisib M, Wittstock M. Transcranial Brain Sonography Findings in Discriminating Between Parkinsonism and Idiopathic Parkinson Disease. Arch Neurol 2007; 64(11): 1635-40.

  28. Okawa M, Miwa H, Kajimoto Y, Hama K, Morita S, Nakanishi I. Transcranial Sonography of the Sustancia negra in Japanese Patients with Parkinson’s Disease or Atypical Parkinsonism: Clinical Potential and Limitations. Intern Med 2007;46(18):1527-31. Epub 2007 Sep 14.

  29. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004;63:504-9.

  30. Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol 2006;253: 448-54.

  31. Tsai CF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson’s disease and vascular parkinsonism. J Neurol 2007; 254: 501-7.

  32. Stockner H, Sojer M, Seppi K, Mueller J, Wenning GK, Schmidauer C. Midbrain Sonography in patients with Essential Tremor. Mov Dosrd 2007; 22(3): 414-7.

  33. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson’s disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007; 130:1799-807.

  34. Schweitzer KJ, Brüssel T, Leitner P, Krüger R, Bauer P, Woitalla D, et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson´s disease. J Neurol 2005; 254:613-6.

  35. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K. Sustancia negra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007; 254(10):1407-13.

  36. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, et al. Ceruloplasmin gene variations and sustancia negra hyperechogenicity in Parkinson disease. Neurology 2004;63:1912-7.

  37. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Krüger R. Funtional relevance of ceruloplasmin mutations in Parkinson´s disease. FASEB J 2005; 19: 1851-3.

  38. Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I. Screening for mutations of the ferritin light and heavy genes in Parkinson’s disease patients with hyperechogenicity of the sustancia negra. Neuroscience Letters 2003; 352: 53-6.

  39. Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U. Screening for mutations of the HFE gene in Parkinson’s disease patients with hyperecho-genicity of the sustancia negra. Neuroscience Letters 2006; 407:16-9.

  40. Hagenah JM, Hedrich K, Becker B, Pramstalller PP, Seidel G, Klein C. Distinguising early-onset PD from dopa-responsive dystonia with trasncranial sonography. Neurology 2006; 66: 1951-2.




2020     |     www.medigraphic.com